With trials on a pandemic pause, Winston & Strawn’s gross revenue declined by roughly 3% to $981.2 million last year. But profits were bolstered by reduced expenses, said firm chairman Tom Fitzgerald, and profits per equity partner increased by 4.6%, to $2.42 million.

Winston had “almost double digits” in terms of the number of scheduled trials postponed in 2020 because of COVID-19, Fitzgerald said in an interview, but he noted that a silver lining was the ability to cut travel and other expenses while maintaining productivity in a remote environment.